Mangement of Pulmonary Emboli
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Pulmonary Embolism (Diagnosis). Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Adherence to International Guidelines Directed Risk Stratification and Management of Acute Pulmonary Embolism, an Egyptian Experience
Overview
To assess to which extent we are adherent to ESC guidelines 2019 in management of patients presented with acute pulmonary embolism
Detailed description
Pulmonary embolism (PE) is the third most frequent cardiovascular disease and is associated with a high mortality burden PE is defined as the obstruction of a pulmonary artery, mostly resulting from the dislodgement of thrombotic material from the lower limbs. It has a wide variety of presentations, ranging from an asymptomatic incidental finding to circulatory collapse and sudden death Pulmonary embolism response teams (PERTs) have emerged as a multidisciplinary team for managing acute pulmonary embolism, with a rapid activation process for multimodality assessment, risk stratification and best management especially for complex challenge cases. PERTs help in improving time to PE diagnosis; shorter time to initiation of anticoagulation reducing hospital length of stay, increasing use of advanced therapies as catheter directed therapies without an increase in bleeding complications with decreasing mortality
Primary outcome measures
- mortality rate [Time frame: 30 day]
Eligibility criteria
Inclusion criteria
- No includion criteria
Exclusion criteria
- No exclusion criteria
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Gerardo F, Faria D, Silverio Antonio P, Baltazar Ferreira J, Beringuilho M, Ferreira H, Fialho I, Miranda I, Sa Pereira Y, Nunes-Ferreira A, Roque D, Santos MB, Morais C, Bravo Baptista S, Augusto JB. PrOgnosis in Pulmonary Embolism (PoPE): 30-Day mortality risk score based on five admission parameters. Rev Port Cardiol. 2024 Jan;43(1):1-8. doi: 10.1016/j.repc.2023.04.011. Epub 2023 Jul 7. English PMID 37423312
- Leidi A, Bex S, Righini M, Berner A, Grosgurin O, Marti C. Risk Stratification in Patients with Acute Pulmonary Embolism: Current Evidence and Perspectives. J Clin Med. 2022 Apr 30;11(9):2533. doi: 10.3390/jcm11092533. PMID 35566658
- Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007 Oct;98(4):756-64. doi: 10.1160/TH07-03-0212. PMID 17938798
- ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014 Oct;12(10):1580-90. doi: 10.1111/jth.12698. PMID 25302663
Identifiers
NCT: NCT06756373 · mangement of pulmonary emboli